臨床泌尿器科76巻11号

2022年10月発行

特集 限局性前立腺癌診療バイブル―このへんでキッチリと前立腺癌診療の“あたりまえ”を整理しよう！ 〈診断〉

限局性前立腺癌における遺伝子診断の意義と将来性

著者： 赤松秀輔¹

所属機関： ¹京都大学大学院医学研究科泌尿器科学

ページ範囲：P.792 - P.796

▶ポイント

・前立腺癌は発癌の段階からドライバーとなる遺伝子異常が異なり，サブタイプに分かれる．

・限局性前立腺癌の多くは前立腺内に多発し，各病巣の遺伝的性質は異なる．

・今後，より詳細に限局性前立腺癌のゲノムについて解明することで，手術期の補助療法を層別化するなど治療を最適化できる可能性がある．

参考文献

1） Network CGAR : The Molecular Taxonomy of Primary Prostate Cancer. Cell 163 : 1011-1025, 2015

2） Robinson D, et al : Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 161 : 1215-1228, 2015

3） Tomlins SA, et al : Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer. Science 310 : 644-648, 2005

4） Kong DP, et al : Prevalence and Clinical Application of TMPRSS2-ERG Fusion in Asian Prostate Cancer Patients : A Large-Sample Study in Chinese People and a Systematic Review. Asian J Androl 22 : 200-207, 2020

5） Cotter K, et al : The Evolving Landscape of Prostate Cancer Somatic Mutations. Prostate 82 （Suppl 1） : S13-S24, 2022

6） Nam RK, et al : Expression of the TMPRSS2 : ERG Fusion Gene Predicts Cancer Recurrence After Surgery for Localised Prostate Cancer. Br J Cancer 97 : 1690-1695, 2007

7） Gopalan A, et al : TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy. Cancer Res 69 : 1400-1406, 2009

8） Pettersson A, et al : The TMPRSS2 : ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes : A Cohort Study and Meta-Analysis. Cancer Epidemiol Biomarkers Prev 21 : 1497-1509, 2012

9） Bernasocchi T, et al : Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer. Nat Commun 12 : 734, 2021

10） Liu D, et al : Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. JCO Precis Oncol 2018 : PO.18.00036, 2018

11） Armenia J, et al : The Long Tail of Oncogenic Drivers in Prostate Cancer. Nat Genet 50 : 645-651, 2018

12） Boysen G, et al : SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. Clin Cancer Res 24 : 5585-5593, 2018

13） Nakazawa M, et al : Clinical and Genomic Features of SPOP-Mutant Prostate Cancer. Prostate 82 : 260-268, 2022

14） Caffo O, et al : Aberrations of DNA Repair Pathways in Prostate Cancer : Future Implications for Clinical Practice? Front Cell Dev Biol 6 : 71, 2018

15） Momozawa Y, et al : Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants. JAMA Oncol 8 : 871-878, 2022

16） Nyberg T, et al : Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers : A Prospective Cohort Study. Eur Urol 77 : 24-35, 2020

17） Hussain M, et al : Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 383 : 2345-2357, 2020

18） Pritchard CC, et al : Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375 : 443-453, 2016

19） Momozawa Y, et al : Germline Pathogenic Variants in 7,636 Japanese Patients with Prostate Cancer and 12,366 Controls. J Natl Cancer Inst 112 : 369-376, 2020

20） Akamatsu S, et al : Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectr 6 : pkac001, 2022

21） Castro E, et al : Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur Urol 68 : 186-193, 2015

22） Halstuch D, et al : Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations. Eur Urol Focus 6 : 212-214, 2020

23） Carter HB, et al : Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur Urol 75 : 743-749, 2019

24） Arora R, et al : Heterogeneity of Gleason Grade in Multifocal Adenocarcinoma of the Prostate. Cancer 100 : 2362-2366, 2004

25） Barry M, et al : TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer : Clinical and Biologic Implications. Urology 70 : 630-633, 2007

26） Furusato B, et al : Mapping of TMPRSS2-ERG Fusions in the Context of Multi-Focal Prostate Cancer. Mod Pathol 21 : 67-75, 2008

27） Boutros PC, et al : Spatial Genomic Heterogeneity Within Localized, Multifocal Prostate Cancer. Nat Genet 47 : 736-745, 2015

28） Cooper CS, et al : Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue. Nat Genet 47 : 367-372, 2015

29） Shoag J, et al : Clinical Variability and Molecular Heterogeneity in Prostate Cancer. Asian J Androl 18 : 543-548, 2016